Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2025 | Looking forward to the upcoming COMy 2025 meeting

Mohamad Mohty • 31 Mar 2025
COMy 2025
Multiple Myeloma

In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his excitement about the upcoming 11th World Congress on Controversies in Multiple Myeloma (COMy), which will be held in Paris, France, on May 15-18, 2025. This event is dedicated to advancing the scientific understanding and clinical management of myeloma, with a comprehensive program highlighting cutting-edge research, innovative therapies, and the latest advancements in patient care.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

A very warm welcome to all of you to the COMY Congress, the World Congress on Controversies in Multiple Myeloma. This will be held in May, on the 15th of May in Paris. We have a fascinating program covering multiple myeloma from biology into the most recent clinical trials. I would kindly invite all of you to join because this is going to be a very exciting opportunity to discover the latest advances in this fascinating disease where we’ve seen amazing progress over the last few years...

A very warm welcome to all of you to the COMY Congress, the World Congress on Controversies in Multiple Myeloma. This will be held in May, on the 15th of May in Paris. We have a fascinating program covering multiple myeloma from biology into the most recent clinical trials. I would kindly invite all of you to join because this is going to be a very exciting opportunity to discover the latest advances in this fascinating disease where we’ve seen amazing progress over the last few years. So please join us in Paris in May 2025 for the COMy Congress.

 

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

More from Mohamad Mohty

Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Mohamad Mohty et al. • 15 Jul 2022
Optimizing conditioning regimens for SCT in AML and MDS 3:38
Optimizing conditioning regimens for SCT in AML and MDS
Mohamad Mohty • 31 Mar 2025
Optimizing anti-CD38 monoclonal antibody-based quadruplet therapies in newly diagnosed myeloma 4:28
Optimizing anti-CD38 monoclonal antibody-based quadruplet therapies in newly diagnosed myeloma
Mohamad Mohty • 31 Mar 2025
Advances that have been made in the treatment of acute & chronic GvHD 5:45
Advances that have been made in the treatment of acute & chronic GvHD
Mohamad Mohty • 31 Mar 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals